The European Medicines Agency (EMA) has accepted Teva Pharmaceutical Industries' Marketing Authorization Application for TEV-‘749, a long-acting injectable form of olanzapine designed for schizophrenia treatment in adults. This new formulation, administered subcutaneously every four weeks, aims to improve treatment adherence and provide a stable, effective option for managing schizophrenia, a condition affecting up to 1.5% of Europeans. TEV-‘749 is supported by clinical trials demonstrating efficacy and safety comparable to oral olanzapine. If approved, it would address a significant gap in long-acting olanzapine treatments and enhance long-term disease management for patients.
Roota, a plant-based topical hair and scalp care brand, offers a roll-on serum and activator spray formulated with rosemary oil, biotin, caffeine, peptides, Redensyl, and AnaGain. The products are designed for targeted application to support the appe...
Calidi Biotherapeutics announced that its 2025 Annual Report included an audit report with an explanatory paragraph highlighting the assumption that the company will continue as a going concern. This disclosure is mandated by the NYSE American Compan...
Michael Saylor, executive chairman of Strategy, revealed that every major US bank, including JPMorgan, Citi, and Bank of America, has contacted him in the past six months for Bitcoin guidance. These banks are moving beyond holding Bitcoin to creating...
Strive, a Bitcoin treasury firm listed on NASDAQ as ASST, raised capital through its SATA preferred stock to purchase 790 Bitcoin in one week, including about 250 Bitcoin in a single day. This purchase more than doubles its previous weekly record of ...
Grocery Outlet Holding's Q1 results revealed a 1% decline in comparable store sales, a 3.1% drop in average transaction size, and a reduced adjusted EBITDA margin of 3.7%. Although promotions increased customer traffic, profitability and basket size ...
